$HBIO News

Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

Harvard Bioscience, Inc. 2026 Q2 - Results - Earnings Call Presentation

Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience Sees FY2026 Sales $89.147M-$90.877M vs $88.600M Est.

Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est

Harvard Bioscience Q2 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $22.727M Beat $21.450M Estimate

Harvard Bioscience, Inc. 2026 Q1 - Results - Earnings Call Presentation

Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New ...

Harvard Bioscience Inc (NASDAQ:HBIO) Q1 Results Show Revenue Miss Offsets Earnings Beat

Harvard Bioscience Announces First Quarter 2026 Financial Results

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Harvard Bioscience Q1 2026 Earnings Call Transcript

Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est

Harvard Bioscience Q1 Adj. EPS $(0.33) Beats $(0.62) Estimate, Sales $20.755M Miss $21.200M Estimate

Harvard Bioscience to Participate in Upcoming Investor Conferences

Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET

Harvard Biosciences shares are trading higher after Benchmark raised its price target on the stock from $0.60 to $6.

Harvard Biosciences shares are trading higher after Benchmark raised its price target on the stock from $0.60 to $6.

Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times